After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

AbbVie, Eli Lilly and Company, Vertex Pharmaceuticals, Thermo Fisher Scientific, and Johnson & Johnson are the five ...

UnitedHealth Group, AbbVie, Eli Lilly and Company, Vertex Pharmaceuticals, and Walmart are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer ...

In a briefing document, the Department of Health said that it cannot currently control the price of a generic medicine if a manufacturer has a mix of branded and unbranded products, and the ...

In this feature, Grünenthal's Florent Edouard and Kate Hurtig outline their principles for a new pharmaceutical marketing ... excellence has been very product-driven. But that approach has ...

The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine) 50 milligram oral tablets, a groundbreaking ...

So, if you look at the yearly free cash flow of the 10 largest pharmaceutical companies, this is a lot of dry powder for acquisitions. The term “top” is rather subjective, as is here a mix of existing ...

Instead, we used a more subjective (but more relevant) mix ... products in 9 different therapeutic areas. 10 products are in phase III clinical trials, 9 in phase II, and 21 in phase I. The Q4 2022 ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...